• Global & Trade
• Tariffs
• February 23, 2026

Scott Whitaker, president and CEO of AdvaMed, the world's largest trade association representing medtech innovators, released the following statement after Fridays' Supreme Court ruling on tariffs. Today, he published a more fulsome readout on LinkedIn, available here .

"Today's ruling by the Supreme Court makes clear that IEEPA cannot be used to levy broad tariffs on markets around the world.

"With that said, we expect the administration will now pursue tariffs through other authorities to meet the President's goal of eliminating trade imbalances and incentivizing U.S. manufacturing.

"As an industry that is primarily U.S.-based, with trade surpluses in most major markets worldwide, we look forward to working with the President and his administration to find a way to help reach his goals of leveling the playing field, addressing foreign trade barriers, and ensuring that the U.S. continues to lead the world in medical innovation and patient care.

"As we move forward, it is essential that America's medtech companies have the certainty and stability we need to invest, innovate and supply U.S. patients with the timely, cost-effective medical technologies they need."

###

Share this article:

• Share this page on Twitter
• Share this page on Facebook
• Share this page on LinkedIn
• Email a link to this page

Related Reading

Event / Emerging Policy Response Resources / Global & Trade / Government & Legislative Affairs / Supply Chain / Tariffs

The Supreme Court Struck Down IEEPA Tariffs - What Medtech Needs To Know

February 26, 2026
1:00 PM - 2:00 PM

Recent court decision may affect your tariff exposure and supply chain strategy. Join us for a live emergency briefing.

News / Global & Trade / Supply Chain / Tariffs

AdvaMed Supports United States-Mexico-Canada Agreement Renewal

February 12, 2026

WASHINGTON-AdvaMed, the Medtech Association, representing more than 650 medtech and health tech companies, the majority small businesses, today expressed support for renewal of the United States-Mexico-Canada Agreement (USMCA). Scott Whitaker, AdvaMed president and CEO, made the following comment on the renewal.

Resource / AdvaMed Advancements / Global & Trade / Tariffs

AdvaMed Plays Tariff Chess, Trump Plays Checkers

February 4, 2026

As tariff uncertainty continues in 2025, AdvaMed plays tariff chess, advocating for predictable, zero-for-zero policies to protect medtech innovation and access.

Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs

AdvaMed® Advancements: Q4 2025 Report

January 27, 2026

AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.

News / China / Global & Trade / Supply Chain / Tariffs

AdvaMed Calls U.S.-China Trade Announcement a "Positive Step" for U.S.-led Medtech

November 3, 2025

WASHINGTON-AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally.

Resource / AdvaMed Advancements / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs

AdvaMed® Advancements: Q3 2025 Report

October 31, 2025

AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more

Resource / Emerging Policy Response Resources / Government & Legislative Affairs / Tariffs / Workforce Advancement

The Economic Impact of the Medical Technology Industry 2024

October 27, 2025

Explore AdvaMed's 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech's vital contributions to the U.S. economy

News / Global & Trade / Supply Chain / Tariffs

AdvaMed Responds to Commerce Department Section 232 National Security Investigation, Seeks Policies to Strengthen U.S. Position as Global Medtech Leader

October 17, 2025

WASHINGTON-AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.'s current level of medtech imports has national security implications. The comments outlined medtech as an American success story and the United States as the global leader in innovating and making the highest quality medtech for the United States and world, an export powerhouse, and much less reliant on medtech imports than sometimes perceived.